These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 33430140)

  • 21. Quinolinic acid-induced increases in calbindin D28k immunoreactivity in rat striatal neurons in vivo and in vitro mimic the pattern seen in Huntington's disease.
    Huang Q; Zhou D; Sapp E; Aizawa H; Ge P; Bird ED; Vonsattel JP; DiFiglia M
    Neuroscience; 1995 Mar; 65(2):397-407. PubMed ID: 7777157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease.
    Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
    Free Radic Biol Med; 2019 Jan; 130():256-266. PubMed ID: 30391672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease.
    Pérez-Navarro E; Canals JM; Ginés S; Alberch J
    Histol Histopathol; 2006 Nov; 21(11):1217-32. PubMed ID: 16874665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
    Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
    Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A; Gidalevitz T; Kristiansen M; Landles C; Woodman B; Wells DJ; Latchman DS; de Belleroche J; Tabrizi SJ; Morimoto RI; Bates GP
    Hum Mol Genet; 2007 May; 16(9):1078-90. PubMed ID: 17360721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased brain tissue sodium concentration in Huntington's Disease - a sodium imaging study at 4 T.
    Reetz K; Romanzetti S; Dogan I; Saß C; Werner CJ; Schiefer J; Schulz JB; Shah NJ
    Neuroimage; 2012 Oct; 63(1):517-24. PubMed ID: 22796981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards a comprehensive understanding of the contributions of mitochondrial dysfunction and oxidative stress in the pathogenesis and pathophysiology of Huntington's disease.
    Tobore TO
    J Neurosci Res; 2019 Nov; 97(11):1455-1468. PubMed ID: 31304621
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Huntington's Disease: Pathogenic Mechanisms and Therapeutic Targets.
    Wright DJ; Renoir T; Gray LJ; Hannan AJ
    Adv Neurobiol; 2017; 15():93-128. PubMed ID: 28674979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac Fas-Dependent and Mitochondria-Dependent Apoptotic Pathways in a Transgenic Mouse Model of Huntington's Disease.
    Wu BT; Chiang MC; Tasi CY; Kuo CH; Shyu WC; Kao CL; Huang CY; Lee SD
    Cardiovasc Toxicol; 2016 Apr; 16(2):111-21. PubMed ID: 25800750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease.
    Glass M; Dragunow M; Faull RL
    Neuroscience; 2000; 97(3):505-19. PubMed ID: 10828533
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroprotective effect of solanesol against 3-nitropropionic acid-induced Huntington's disease-like behavioral, biochemical, and cellular alterations: Restoration of coenzyme-Q10-mediated mitochondrial dysfunction.
    Mehan S; Monga V; Rani M; Dudi R; Ghimire K
    Indian J Pharmacol; 2018; 50(6):309-319. PubMed ID: 30783323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Widespread heterogeneous neuronal loss across the cerebral cortex in Huntington's disease.
    Nana AL; Kim EH; Thu DC; Oorschot DE; Tippett LJ; Hogg VM; Synek BJ; Roxburgh R; Waldvogel HJ; Faull RL
    J Huntingtons Dis; 2014; 3(1):45-64. PubMed ID: 25062764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New Perspectives on the Neuropathology in Huntington's Disease in the Human Brain and its Relation to Symptom Variation.
    Waldvogel HJ; Kim EH; Thu DC; Tippett LJ; Faull RL
    J Huntingtons Dis; 2012; 1(2):143-53. PubMed ID: 25063328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mechanisms of neuronal death in Huntington's disease. Second part: therapeutic challenges].
    Bantubungi K; Blum D
    Rev Med Brux; 2007; 28(6):487-94. PubMed ID: 18265808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative damage in Huntington's disease pathogenesis.
    Browne SE; Beal MF
    Antioxid Redox Signal; 2006; 8(11-12):2061-73. PubMed ID: 17034350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondria and neurodegeneration.
    Petrozzi L; Ricci G; Giglioli NJ; Siciliano G; Mancuso M
    Biosci Rep; 2007 Jun; 27(1-3):87-104. PubMed ID: 17486441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Excitatory amino acid binding sites in the caudate nucleus and frontal cortex of Huntington's disease.
    Dure LS; Young AB; Penney JB
    Ann Neurol; 1991 Dec; 30(6):785-93. PubMed ID: 1665055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
    Beal MF
    Ann Neurol; 1992 Feb; 31(2):119-30. PubMed ID: 1349466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder.
    Rosser AE; Busse ME; Gray WP; Badin RA; Perrier AL; Wheelock V; Cozzi E; Martin UP; Salado-Manzano C; Mills LJ; Drew C; Goldman SA; Canals JM; Thompson LM
    Brain; 2022 Jun; 145(5):1584-1597. PubMed ID: 35262656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.
    Cha JH; Frey AS; Alsdorf SA; Kerner JA; Kosinski CM; Mangiarini L; Penney JB; Davies SW; Bates GP; Young AB
    Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):981-9. PubMed ID: 10434296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.